International Agency for Research on Cancer (IARC) - Summaries & Evaluations
1,4-BUTANEDIOL DIMETHANESULFONATE (MYLERAN)
VOL.: 4 (1974) (p. 247)
5. Summary of Data Reported and Evaluation
5.1 Animal carcinogenicity data
Administration of 1,4-butanediol dimethanesulfonate (Myleran) to the
mouse by intraperitoneal injection and to the rat by oral
administration did not significantly increase the incidence of
tumours. Intravenous administration in the mouse significantly
increased the incidence of thymic lymphomas and ovarian tumours.
Myleran in conjunction with X-rays further augmented the incidence of
thymic lymphomas. The increased incidences of thymic lymphomas and
ovarian tumours are difficult to assess with respect to the
carcinogenicity of Myleran in the mouse.
5.2 Human carcinogenicity data
Although there is evidence that histological and cytological changes
are associated with Myleran therapy, there is no firm evidence of an
increased cancer risk among those treated.
Subsequent evaluation: Suppl. 7 (1987)
Last updated: 17 March 1998